WO2008036966A3 - Methods and compositions for the treatment of inflammation, obesity and related metabolic disorders - Google Patents

Methods and compositions for the treatment of inflammation, obesity and related metabolic disorders Download PDF

Info

Publication number
WO2008036966A3
WO2008036966A3 PCT/US2007/079284 US2007079284W WO2008036966A3 WO 2008036966 A3 WO2008036966 A3 WO 2008036966A3 US 2007079284 W US2007079284 W US 2007079284W WO 2008036966 A3 WO2008036966 A3 WO 2008036966A3
Authority
WO
WIPO (PCT)
Prior art keywords
inflammation
obesity
compositions
treatment
methods
Prior art date
Application number
PCT/US2007/079284
Other languages
French (fr)
Other versions
WO2008036966A2 (en
Inventor
Indira Padmalayam
Debnath Bhuniya
Dumbala Srinivas Reddy
Ish K Khanna
Uday Saxena
Sivaram Pillarisetti
Original Assignee
Reddy Us Therapeutics Inc
Indira Padmalayam
Debnath Bhuniya
Dumbala Srinivas Reddy
Ish K Khanna
Uday Saxena
Sivaram Pillarisetti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reddy Us Therapeutics Inc, Indira Padmalayam, Debnath Bhuniya, Dumbala Srinivas Reddy, Ish K Khanna, Uday Saxena, Sivaram Pillarisetti filed Critical Reddy Us Therapeutics Inc
Publication of WO2008036966A2 publication Critical patent/WO2008036966A2/en
Publication of WO2008036966A3 publication Critical patent/WO2008036966A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Abstract

This invention provides a method of reducing inflammation in a living cell of a subject. This method increases the level of lipoic acid synthase within the living cell thereby causing the reduction of the inflammation. Various embodiments and variants are contemplated, some of which are set forth in claim format at the end of this document. The aspects, embodiments, and variants so exemplified in the claims format should not be understood as limiting the invention.
PCT/US2007/079284 2006-09-22 2007-09-24 Methods and compositions for the treatment of inflammation, obesity and related metabolic disorders WO2008036966A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84650106P 2006-09-22 2006-09-22
US60/846,501 2006-09-22

Publications (2)

Publication Number Publication Date
WO2008036966A2 WO2008036966A2 (en) 2008-03-27
WO2008036966A3 true WO2008036966A3 (en) 2008-11-06

Family

ID=39201358

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/079284 WO2008036966A2 (en) 2006-09-22 2007-09-24 Methods and compositions for the treatment of inflammation, obesity and related metabolic disorders

Country Status (1)

Country Link
WO (1) WO2008036966A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8524656B2 (en) 2008-07-08 2013-09-03 Jacques Galipeau GM-CSF and truncated CCL2 conjugates and methods and uses thereof
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013116238A1 (en) * 2012-01-30 2013-08-08 Sanrx Pharmaceuticals, Inc. Calcium folate (cafolate) and therapeutic methods based thereon

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040235123A1 (en) * 2001-04-20 2004-11-25 Liao Hans H Production of alpha-lipoic acid
WO2006088246A1 (en) * 2005-02-18 2006-08-24 Takeda Pharmaceutical Company Limited Agent for controlling function of gpr34 receptor

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040235123A1 (en) * 2001-04-20 2004-11-25 Liao Hans H Production of alpha-lipoic acid
WO2006088246A1 (en) * 2005-02-18 2006-08-24 Takeda Pharmaceutical Company Limited Agent for controlling function of gpr34 receptor

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ALDONYTE ET AL.: "Circulating monocytes from healthy individuals and COPD patients", RESPIRATORY RESEARCH, 2003, XP021000001 *
DATABASE CAPLUS [online] ITO ET AL.: "Preparation of N-acyl-amino derivatives for controlling functions of GRP34 receptor as antagonists or inverse agonists", Database accession no. (145:293345) *
JANG ET AL.: "Analysis of proteome and transcriptome of tumor necrosis factor alpha stimulated vascular smooth muscle cells with or without alpha lipoic acid", PROTEOMICS, vol. 4, 2004, pages 3383 - 3393 *
MERVAALA ET AL.: "Lipoic acid supplementation prevents angiotensin II-induced renal injury", KIDNEY INTERNATIONAL, vol. 64, 2003, pages 501 - 508 *

Also Published As

Publication number Publication date
WO2008036966A2 (en) 2008-03-27

Similar Documents

Publication Publication Date Title
ZA200907928B (en) Synethoc bile acid composition, method, and preparation
HK1219306A1 (en) Methods and compositions for sleep disorders and other disorders
HK1209628A1 (en) Methods, compounds, compositions and vehicles for delivering 3-amino- 1-propanesulfonic acid 3--1-
EP2013932A4 (en) Dendritic metal nanostructures for fuel cells and other applications
GB0907315D0 (en) Polymeric acid precursor compositions and methods
IL185977A0 (en) Dendritic cell compositions and methods
LT2894165T (en) Methods and compositions for treating complement-associated disorders
IL205318A0 (en) Compositions comprising electrochemically altered aqueous fluids and uses thereof for treating inflammation
ZA200807626B (en) Methods for regulating inflammatory mediators and peptides useful therein
PL2009122T3 (en) Copper-zinc alloy, method for its manufacture and use
WO2007101161A8 (en) Methods and compositions for the treatment of gastrointestinal disorders
WO2009111586A3 (en) Autonomous in vitro evolution
AU2007243282A8 (en) Compositions and methods for the treatment of cardiovascular disease
GB2465814B (en) Method,composition and device for the treatment of enzymes and saccharides disorders
EP2269981A4 (en) Vinylsulfonic acid, polymer of the same, and method for producing the same
WO2008036966A3 (en) Methods and compositions for the treatment of inflammation, obesity and related metabolic disorders
WO2009008997A3 (en) Treatment of neuropathic pain
EP2205771A4 (en) Method, alloy and component
GB0719367D0 (en) Transcription factor decoys, compositions and methods
IL198286A0 (en) Use of an indazolemethoxyalkanoic acid for reducing triglyceride, cholesterol and glucose levels
EP1973874A4 (en) Low protonation constant hydroxy acids
WO2009124252A3 (en) Methods and compositions for the treatment of rheumatoid arthritis and other inflammatory diseases
WO2009088939A3 (en) Compositions and methods for treating neurodegenerative diseases
WO2010037130A3 (en) Compositions and methods of generating reprogrammed adipocyte cells and methods of use therefore
WO2010023658A3 (en) Compositions and methods for the treatment of glioblastoma

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07843053

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07843053

Country of ref document: EP

Kind code of ref document: A2